U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030

U.S. Androgenetic Alopecia Market Trends

The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).

Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.

The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.

Market Concentration & Characteristics

The market growth stage is high, and the pace of growth is accelerating. The degree of innovation in the U.S. androgenetic alopecia industry is high, driven by increasing R&D investments in advanced treatments. Companies are developing novel therapies such as topical foams and oral medications alongside emerging technologies such as low-level laser therapy (LLLT) and stem cell-based treatments. In January 2021, HairMax introduced the Flip 80 Laser Cap, a cordless device that treats hair loss by flipping to cover the front or back of the scalp.    

The level of M&A activity is moderate as key players seek to expand their product portfolios and market reach. Strategic partnerships and collaborations are also increasing, allowing companies to pool resources for faster drug development and commercialization. For instance, in December 2023, Aclaris Therapeutics, Inc. entered into a patent license agreement with Sun Pharma for using deuruxolitinib to treat androgenetic alopecia (AGA) or alopecia areata (AA).

Treatment Insights

The pharmaceuticals segment accounted for the largest revenue share of 98.3% in 2024, primarily due to the widespread use of FDA-approved medications such as minoxidil and finasteride, which remain the gold standard for hair loss treatment.  Furthermore, the rising volume of clinical trials and ongoing product development initiatives is anticipated to accelerate segment growth further. 

The devices segment is projected to grow at the fastest CAGR of 6.8% from 2025 to 2030, driven by increasing demand for non-invasive, at-home hair loss solutions. Devices based on low-level laser therapy (LLLT) offer the convenience of at-home use and minimize the need for clinical visits. 

End Use Insights

The dermatology clinics segment held the largest market share in 2024, driven by the growing prevalence of hair disorders and rising consumer awareness about early intervention, which has driven more individuals to seek professional medical advice rather than self-treatment. In addition, the expansion of aesthetic dermatology services and the integration of innovative technologies (such as robotic hair transplants) in clinics enhance patient outcomes and satisfaction. In Texas, U.S, Austin Hair Restoration Clinic offers ARTAS robotic technology alongside other advanced treatments, offering only thoroughly tested and effective hair restoration solutions.

The homecare settings segment is projected to grow at the fastest CAGR from 2025 to 2030, fueled by shifting consumer preferences toward convenient, discreet, cost-effective hair loss solutions. The rise of direct-to-consumer (DTC) telehealth platforms and online pharmacies has made prescription treatments more accessible without in-person clinic visits.

Sales Channel Insights

The prescription segment dominated the U.S. androgenetic alopecia industry in 2024, reflecting strong demand for clinically proven, physician-supervised treatments. This growth is driven by the widespread adoption of FDA-approved prescription medications and compounded topical formulations, which are considered more effective than OTC alternatives for moderate-to-severe cases. Dermatologists increasingly recommend these treatments due to their well-documented efficacy in halting hair loss progression and stimulating regrowth.

The OTC segment is expected to grow at the fastest CAGR over the forecast period. The patent expirations of key FDA-approved therapies such as Avodart (dutasteride), Rogaine (minoxidil), and Propecia (finasteride) have led to a significant increase in the availability of generic alternatives. Increasing consumer preference for convenient, accessible, and affordable hair loss treatments. Rising awareness about hair loss and its early management, combined with the availability of effective OTC products, drives demand. In addition, easy access through pharmacies and online platforms, along with growing aesthetic consciousness and desire for self-care solutions, supports the segment’s rapid growth.

Gender Insights

The male segment accounted for the largest share in 2024. Androgenetic alopecia, or male pattern baldness, represents over 95% of hair loss cases in men, according to the American Hair Loss Association. The condition affects two-thirds of American men by age 35, with prevalence rising to approximately 85% by age 50. This high incidence drives consistent demand for hair loss treatments in the U.S. market.

The female segment is expected to witness considerable growth from 2025 to 2030. Increasing awareness among women contributes to this growth. Growing awareness through digital platforms and celebrity endorsements of normalized hair loss treatments has boosted adoption.

Key U.S. Androgenetic Alopecia Company Insights

Some key companies in the U.S. androgenetic alopecia industry include Johnson & Johnson Services, Inc., Cipla, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc. 

• Johnson & Johnson Services, Inc. is a global healthcare company focusing on pharmaceuticals and medical technology. Its offerings cover areas such as immunology, oncology, infectious diseases, neuroscience, cardiovascular health, and surgical care. In the context of androgenetic alopecia, the company offers various products, including Rogaine (minoxidil), an over-the-counter topical treatment that promotes hair regrowth in both men and women.

• HairMax International, LLC is a key player in at‑home laser phototherapy technology for hair regrowth. It specializes in continuous innovation and offers a full suite of laser-based products, including LaserCombs, LaserBands, and LaserCaps, designed to stimulate follicle activity and support hair growth through low-level laser therapy.

Recent Developments

• In May 2023, Kintor Pharmaceuticals completed a Phase II trial of KX-826 of treating males with androgenetic alopecia in the U.S.

U.S. Androgenetic Alopecia Market Report Scope

U.S. Androgenetic Alopecia Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceuticals

  • Devices

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Homecare Settings

  • Dermatology Clinics

• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescriptions

  • OTC

• Gender Outlook (Revenue, USD Million, 2018 - 2030)

  • Male

  • Female